Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428626 | 0.91 | JAK2 (0.47) | IRAK4JAK2NTRK1RETPIM1 | |
| SCHEMBL404423 | 0.82 | HTT (0.60) | HTTIRAK4NTRK1RETPIM1 | |
| SCHEMBL405674 | 0.81 | IRAK4 (0.45) | IRAK4JAK2NTRK1RETPIM1 | |
| SCHEMBL404555 | 0.80 | HTT (0.55) | HTTIRAK4JAK2NTRK1RET | |
| SCHEMBL402942 | 0.79 | HTT (0.61) | HTTIRAK4NAMPTJAK2NTRK1 | |
| SCHEMBL405010 | 0.79 | PIM1 (0.47) | HTTIRAK4JAK2NTRK1RET | |
| SCHEMBL10191618 | 0.78 | NTRK1 (0.54) | IRAK4JAK2NTRK1JAK1TYK2 | |
| SCHEMBL403237 | 0.78 | RET (0.58) | HTTIRAK4NTRK1RETPIM1 | |
| SCHEMBL403721 | 0.78 | RET (0.55) | HTTIRAK4NTRK1RETPIM1 | |
| SCHEMBL403563 | 0.78 | JAK2 (0.54) | IRAK4JAK2NTRK1RETPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | HTT 4391/4885IRAK4 9/4885NAMPT 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.